Cover Image
市場調查報告書

搭配診斷檢驗的全球市場

The World Market for Companion Diagnostic Tests

出版商 Kalorama Information 商品編碼 360878
出版日期 內容資訊 英文 810 Pages
訂單完成後即時交付
價格
Back to Top
搭配診斷檢驗的全球市場 The World Market for Companion Diagnostic Tests
出版日期: 2016年06月07日 內容資訊: 英文 810 Pages
簡介

本報告提供全球搭配診斷及個體化醫療診斷市場相關調查,應用,經營模式,及促進成長要素、課題等的分析,主要企業簡介,為您概述為以下內容。

第1章 摘要整理

第2章 簡介

第3章 個體化醫療的現行、新興應用

  • 癌症 (固態腫瘤、血液癌症)
  • 心血管疾病
  • 神經疾病
  • 自體免疫、發炎性疾病:其他免疫相關疾病
  • 感染疾病
  • 治療藥監測
  • 藥物代謝
  • 個體化醫療檢驗的其他應用

第4章 經營模式、契約:個體化醫療、搭配診斷

  • 經營模式
  • 投資、融資契約
  • M&A
  • 醫藥品、診斷企業的合作
  • 其他的醫藥品企業的協定
  • 診斷企業與其他 (非醫藥品) 企業的合作
  • 跟診斷企業和大學、非營利研究機關的合作

第5章 個體化醫療、搭配診斷:市場成長的促進要素、課題

  • 癌症診斷市場促進要素
  • 開發藥劑中搭配診斷檢驗:機會、課題
  • 新生物標記或遺傳基因標記臨床評估
  • 搭配診斷的法規
  • 搭配診斷檢驗、類似的治療藥的複雜度
  • 指南
  • 實驗室開發檢驗、FDA
  • 技術的進步改變個體化醫療診斷的未來
  • 醫療費償付
  • 醫生的教育,接納,及新個體化醫療檢驗的利用
  • 競爭
  • 未來展望、其他

第6章 個體化醫療、搭配診斷:市場分析

  • 全球個體化醫療及搭配診斷檢驗市場:各地區
  • 個體化醫療、搭配診斷檢驗市場:各疾病的徵兆
  • 個體化醫療檢驗服務市場

第7章 企業簡介:醫藥品企業 (搭配診斷活動的焦點)

第8章 企業簡介:診斷企業、臨床實驗室

目錄
Product Code: KLI15021881

The emergence of companion diagnostic tests, tests that identify which patients are expected to benefit from treatment with a specific therapy, has established a relatively new category of cancer test. Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics provide insight into understanding disease processes and ways that medicines can work to counteract disease. This report, The World Market for Companion Diagnostics, covers the world market for companion diagnostic and personalized medicine diagnostics.

Market analysis in this report covers the world market for companion diagnostics, including:

  • World IVD Companion Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020
  • World IVD Companion Diagnostics Test Market by Disease Segment, 2015 (Cancer, Other)
  • Worldwide Companion Diagnostics Test Services Market, 2015 and 2020

The phrase "Companion Diagnostics Market" includes both the personalized medicine market and FDA-defined companion diagnostics. The personalized medicine market is a large and rapidly growing market, as researchers, pharmaceutical companies, and diagnostic companies are now starting to develop personalized medicine tests. Most of the market growth to date has been in oncology, but there remains considerable opportunity for this rapid growth in this and other areas. The report examines current and emerging applications of personalized medicine, including:

  • Selected Major Biomarkers in Oncology Personalized Medicine Tests
  • Selected Companies with Personalized Medicine Tests for Oncology
  • Selected Companies with Personalized Medicine Tests for Cardiovascular Disease/Disorders
  • Selected Companies with Personalized Medicine Tests for Neurological Disorders
  • Selected Companies with Personalized Medicine Tests for Autoimmune and Inflammatory Disorders; Other Immune Related Conditions
  • Selected Biomarkers and Other Tests for Antibiotic Resistance, and Companies Developing/Marketing these Biomarkers
  • Selected Companies with Other Personalized Medicine Infectious Disease Tests
  • Selected Companies with Personalized Medicine Tests for Therapeutic Drug Monitoring of Biological Drugs
  • Pharmacogenomic Biomarkers in Drug Labeling
  • Selected Companies with Personalized Medicine Tests for Drug Metabolism Genes
  • Selected Companies with Other Personalized Medicine Tests

Companies working in the field of personalized medicine need to understand both the pharmaceutical and diagnostic markets (including regulatory and other issues), but many companies do not have expertise in both fields. This has lead to many agreements and acquisitions, and a large number of diverse deals are discussed in this report, including:

  • Investments and Financings in Personalized Medicine/Companion Diagnostics
  • Selected Examples of Pharmaceutical Companies and Other Companies That Invested in Diagnostic Companies in Personalized Medicine
  • Mergers and Acquisitions in Personalized Medicine/Companion Diagnostics
  • Selected Examples of Pharmaceutical Companies That Acquired Diagnostic Companies or Have Diagnostic Divisions
  • Collaborations between Pharmaceutical and Diagnostic Companies
  • Selected Examples of Pharmaceutical That Entered into Agreements with Diagnostic Companies
  • Selected Other Pharmaceutical Company Agreements
  • Collaborations between Two Diagnostic Companies
  • Diagnostic Company Agreements with Clinical Laboratories
  • Diagnostic Company Agreements with Other Companies
  • Diagnostic Company Collaborations with Universities and Other Non-Profit Research Institutes (Including Government)

The growth in companion diagnostic testing is likely to continue, as many new therapies are being developed and commercialized. The emergence of these new therapies presents opportunities and also challenges for the diagnostics industry. Oncology is the largest segment of the personalized medicine market, and so market drivers for the cancer diagnostic market also drive the overall personalized medicine and companion diagnostics markets. The report discusses this and other market drivers and challenges in personalized medicine and companion diagnostics.

The World Market for Companion Diagnostics provides profiles of selected pharmaceutical companies that are active in the fields of companion diagnostics or personalized medicine. They include companies that market drugs that have associated companion diagnostic tests, pharmaceutical companies that are collaborating with diagnostic companies to develop companion diagnostic tests, and companies with their own internal capabilities and activities in companion diagnostics. These include:

  • AbbVie Inc.
  • Acumen Pharmaceuticals, Inc.
  • Adaptimmune Therapeutics plc
  • Amgen Inc.
  • ARCA biopharma, Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Arno Therapeutics, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Athera Biotechnologies AB
  • AVEO Oncology
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Eli Lilly
  • Galena Biopharma, Inc.
  • GlaxoSmithKline plc
  • Idera Pharmaceuticals, Inc.
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono)
  • Novartis AG
  • Pfizer Inc.
  • Roche (F. Hoffmann-La Roche Ltd.) and Genentech (A Member of the Roche Group)

The report also includes profiles of companies that are active in the discovery and/or commercialization of companion diagnostics or other in vitro diagnostic tests for personalized medicine. This includes diagnostic companies that market kits that are used by clinical laboratories, and also diagnostic companies that are commercializing their novel diagnostic tests as a service offered to physicians, with the tests performed in the company's own CLIA certified laboratory. These include:

  • 20/20 GeneSystems, Inc.
  • A&G Pharmaceutical, Inc.
  • Abacus Diagnostica Oy
  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Acobiom
  • ACT Genomics Co., Ltd.
  • Adaptive Biotechnologies Corporation
  • Admera Health (A GENEWIZ Company)
  • Advanced Cell Diagnostics
  • Aelan Cell Technologies
  • Affymetrix, Inc. (Acquired by Thermo Fisher Scientific)
  • Agena Bioscience Inc.
  • Agendia NV
  • Almac Group Limited
  • AltheaDx, Inc.
  • Amarantus BioScience Holdings, Inc.
  • Amoy Diagnostics Co., Ltd.
  • ANGLE plc
  • ARKRAY, Inc.
  • Assurex Health, Inc.
  • Asuragen, Inc.
  • Atlas Genetics Ltd
  • AutoGenomics, Inc.
  • Avant Diagnostics, Inc.
  • BacterioScan, Inc.
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
  • Becton, Dickinson and Company (BD)
  • BG Medicine, Inc.
  • Biocartis
  • Biocept, Inc.
  • Biodesix, Inc.
  • BioFire Diagnostics, LLC. (Acquired by bioMérieux)
  • BioGenex
  • Biological Dynamics, Inc.
  • BioMarker Strategies
  • bioMérieux SA
  • BioMosaics Inc.
  • BioReference Laboratories, Inc. (BRLI) (Part of OPKO Health, Inc.)
  • bioTheranostics, Inc.
  • Biotype Diagnostic GmbH
  • Cancer Genetics, Inc.
  • Caprion, Inc.
  • CardioDx, Inc.
  • CardioGenics Holdings Inc.
  • CareDx, Inc.
  • Caris Life Sciences
  • Castle Biosciences, Inc.
  • Cepheid
  • Clarient Diagnostic Services, Inc. (A NeoGenomics Company)
  • CompanionDx
  • Crescendo Bioscience (A Myriad Company)
  • Cube Dx GmbH
  • Curetis AG
  • Cynvenio Biosystems, Inc.
  • Dako A/S (An Agilent Company)
  • Danaher Corporation
  • Definiens AG (Acquired by MedImmune, Part of AstraZeneca)
  • DiaCarta, Inc.
  • DiamiR, LLC
  • Diatech Pharmacogenetics srl
  • Diaxonhit
  • DNA Electronics Ltd. (DNAe)
  • EntroGen, Inc.
  • Enzo Biochem, Inc
  • Enzo Life Sciences, Inc.
  • Enzo Clinical Labs, Inc.
  • Epic Sciences, Inc.
  • Eutropics Pharmaceuticals
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • GeneCentric Diagnostics, Inc.
  • Genection, Inc. (An Invivoscribe Company)
  • Genelex Corporation
  • GeneNews Limited and Innovative Diagnostic Laboratory
  • Genomas, Inc.
  • GenomeDx Biosciences
  • Genomic Health, Inc.
  • Genomica S.A.U.
  • Genomind
  • Genoptix (A Novartis Company)
  • GenPath Oncology
  • Grifols, S.A.
  • Guardant Health, Inc.
  • HalioDx
  • Harmonyx Diagnostics
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Inform Genomics, Inc.
  • Inivata Ltd.
  • Insight Genetics, Inc.
  • InSilixa, Inc.
  • IntegraGen SA
  • Invivoscribe Technologies, Inc.
  • Iris BioTechnologies Inc.
  • Janssen Diagnostics/Janssen Diagnostics BVBA/Janssen Diagnostics, LLC/Janssen Diagnostics, LLC
  • Lab 21 (Part of the Novacyt Group of Companies)
  • Laboratory Corporation of America (LabCorp)
  • Leica Biosystems Inc. (A Danaher Company)
  • Luminex Corporation
  • Mayo Medical Laboratories and Mayo Clinic
  • Medical & Biological Laboratories Co., Ltd. (MBL)
  • MBL International Corporation
  • Metabolon, Inc.
  • Metamark Genetics, Inc.
  • MIODx
  • MolecularMD Corporation
  • Monogram Biosciences (LabCorp Specialty Testing Group)
  • Multiplicom NV
  • Myriad Genetics, Inc.
  • Myriad RBM, Inc.
  • NanoString Technologies, Inc.
  • NantOmics (Member of the NantWorks ecosystem of companies)
  • NeoGenomics, Inc./NeoGenomics Laboratories
  • NewGene Ltd.
  • New Oncology AG
  • NovellusDx
  • Nuclea Biotechnologies, Inc.
  • OncoDNA SA
  • Oncompass GmbH
  • OncoPlex Diagnostics (OncoPlexDx)(Part of NantOmics)
  • Oncospire Genomics
  • One Way Liver S.L. (OWL Metabolomics)
  • OPKO Health, Inc./OPKO Diagnostics
  • OvaGene Oncology Inc.
  • Oxford Cancer Biomarkers Ltd.
  • Oxford Gene Technology
  • Panagene Inc.
  • Personal Genome Diagnostics, Inc.
  • Protagen AG
  • QIAGEN N.V.
  • QuanDx Inc.
  • Quest Diagnostics
  • Qvella Corporation
  • RiboMed Biotechnologies, Inc.
  • Roche
  • Rosetta Genomics Ltd.
  • Siemens Healthcare Diagnostics
  • Siemens Clinical Laboratory
  • Symbiodx
  • Sysmex Corporation
  • Theranostics Health Inc. (Acquired by Avant Diagnostics, Inc.)
  • Thermo Fisher Scientific, Inc.
  • Transgenomic, Inc.
  • TrimGen Corporation
  • Trovagene, Inc.
  • Ventana Medical Systems, Inc. (Member of the Roche Group)
  • WOUNDCHEK Laboratories

The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Overview
  • Scope and Methodology
  • Market Overview
  • Prognosis for Growth

TWO: INTRODUCTION

  • Terms Used in Companion Diagnostics and Personalized Medicine
  • Definitions of Companion Diagnostics and Personalized Medicine Used in This Report
  • Types of Tests Included in Personalized Medicine
  • Technology Used in Personalized Medicine
  • Point of View

THREE: CURRENT AND EMERGING APPLICATIONS OF PERSONALIZED MEDICINE

  • Oncology (Solid Tumors and Hematological Cancers)
  • Cardiovascular Disease
  • Neurological Disorders
  • Autoimmune and Inflammatory Disorders; Other Immune Related Conditions
  • Infectious Disease
    • Antibiotic Resistance
    • Other Infectious Disease Personalized Medicine Tests
  • Therapeutic Drug Monitoring
  • Drug Metabolism
  • Other Applications of Personalized Medicine Tests

FOUR: BUSINESS MODELS AND DEALS - PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS

  • Business Models
    • Business Models for Pharmaceutical Companies in Personalized Medicine
    • Business Models for Diagnostic Companies in Personalized Medicine
  • Investments and Financing Agreements
  • Mergers and Acquisitions
  • Collaborations between Pharmaceutical and Diagnostic Companies
  • Other Pharmaceutical Company Agreements
  • Diagnostic Company Collaborations with Other (Non-Pharmaceutical) Companies
  • Diagnostic Company Collaborations with Universities and Non-Profit Research
  • Institutes

FIVE: PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS - MARKET DRIVERS AND CHALLENGES

  • Cancer Diagnostic Market Drivers
  • Companion Diagnostic Tests in Drug Development - Opportunities and Challenges
  • Clinical Validation of Novel Biomarkers or Genetic Signatures
  • Regulation of Companion Diagnostics
  • Complexities of Companion Diagnostic Tests and Corresponding Therapeutic
  • Products; Harmonization of Companion Diagnostic Tests across a Class of Targeted
  • Therapies
  • Guidelines
  • Laboratory Developed Tests and the FDA
  • Limited Tissue from Biopsies for Growing Number of Cancer Tests
  • Advances in Technology Changing the Future of Personalized Medicine Diagnostics .. 277
  • Reimbursement
  • Physician Education, Acceptance, and Use of Novel Personalized Medicine Tests
  • Competition
  • Working Together on Personalized Medicine - Alliances, Consortiums, and Other
  • Groups
  • Future Prospects

SIX: PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS - MARKET ANALYSIS

  • Global Personalized Medicine and Companion Diagnostic Test Market by
  • Geographical Region
  • Personalized Medicine and Companion Diagnostic Test Market by Disease
  • Indication
  • Personalized Medicine Testing Services Market

SEVEN: COMPANY PROFILES: PHARMACEUTICAL COMPANIES (FOCUSINGON COMPANION DIAGNOSTIC ACTIVITIES)

  • AbbVie Inc.
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Acumen Pharmaceuticals, Inc.
  • Adaptimmune Therapeutics plc
    • Recent Revenue History
    • Company Overview
  • Amgen Inc.
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • ARCA biopharma, Inc.
    • Recent Revenue History
    • Company Overview
  • ARIAD Pharmaceuticals, Inc.
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Arno Therapeutics, Inc.
    • Recent Revenue History
    • Company Overview
  • Array BioPharma Inc.
    • Recent Revenue History
    • Company Overview
  • Astellas Pharma Inc.
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • AstraZeneca
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Athera Biotechnologies AB
  • AVEO Oncology
    • Recent Revenue History
    • Company Overview
  • Bayer AG
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Boehringer Ingelheim
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Bristol-Myers Squibb Company
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Celldex Therapeutics, Inc.
    • Recent Revenue History
    • Company Overview
  • Clovis Oncology, Inc.
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Eli Lilly
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Galena Biopharma, Inc.
    • Recent Revenue History
    • Company Overview
  • GlaxoSmithKline plc
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Idera Pharmaceuticals, Inc
    • Recent Revenue History
    • Company Overview
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Merck & Co., Inc.
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Merck KGaA (EMD Serono)
  • Novartis AG
    • Recent Revenue History
  • Companion Diagnostics/Personalized Medicine Activities
  • Pfizer Inc.
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities
  • Roche (F. Hoffmann-La Roche Ltd.) and Genentech (A Member of the
  • Roche Group)
    • Recent Revenue History
    • Companion Diagnostics/Personalized Medicine Activities

EIGHT: COMPANY PROFILES: DIAGNOSTIC COMPANIES AND CLINICAL LABORATORIES

  • 20/20 GeneSystems, Inc
  • A&G Pharmaceutical, Inc.
  • Abacus Diagnostica Oy
  • Abbott Laboratories
    • Recent Revenue History
    • Company Overview - Focusing on Personalized Medicine and Companion
    • Diagnostics
    • Agreements with Pharmaceutical Companies
    • Acquisitions and Other Agreements with Other Companies
  • Accelerate Diagnostics, Inc.
    • Recent Revenue History
    • Company Overview
  • Acobiom
  • ACT Genomics Co., Ltd.
  • Adaptive Biotechnologies Corporation
  • Admera Health (A GENEWIZ Company)
  • Advanced Cell Diagnostics
    • Products
    • Services for Pharmaceutical Companies
    • Companion Diagnostics Agreements
  • Aelan Cell Technologies
  • Affymetrix, Inc. (Acquired by Thermo Fisher Scientific)
    • Recent Revenue History
    • Company Overview
    • eBioscience
    • Affymetrix Core
    • Selected Affymetrix Agreements
  • Agena Bioscience Inc.
  • Agendia NV
  • Almac Group Limited
  • AltheaDx, Inc.
  • Amarantus BioScience Holdings, Inc.
    • Amarantus Diagnostics
  • Amoy Diagnostics Co., Ltd.
  • ANGLE plc
  • ARKRAY, Inc.
  • Assurex Health, Inc.
  • Asuragen, Inc.
    • Diagnostic Products
    • Translational/Companion Diagnostics
    • Agreements
  • Atlas Genetics Ltd
  • AutoGenomics, Inc.
  • Avant Diagnostics, Inc.
  • BacterioScan, Inc.
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
    • Recent Revenue History
    • Company Overview
    • Flow Cytometry
    • Beckman Coulter Genomics
    • Other Tests and Services
    • Agreements
  • Becton, Dickinson and Company (BD)
    • Recent Revenue History
    • Company Overview
    • Microbiology and Molecular Diagnostic Testing for Infectious Diseases
    • Fluorescence-Activated Cell Sorters and Analyzers
    • Oncology
  • BG Medicine, Inc.
    • Recent Revenue History
    • Company Overview
  • Biocartis
    • Recent Revenue History
    • Company Overview
    • Startup History
    • Technology/Products
    • Investors/Financings and IPO
    • Pharmaceutical Company Agreements
    • Other Agreements
  • Biocept, Inc.
    • Recent Revenue History
    • Company Overview
    • Financings
    • Agreements with Pharmaceutical Companies
    • Other Agreements
  • Biodesix, Inc.
    • Investors/Financings
    • Other Agreements
  • BioFire Diagnostics, LLC. (Acquired by bioMérieux)
    • Recent Revenue History and Other Financial Information
    • Company Overview
  • BioGenex
  • Biological Dynamics, Inc.
  • BioMarker Strategies
  • bioMérieux SA
    • Recent Revenue History
    • Company Overview
    • Traditional Microbiology
    • Immunodiagnostics for Lab Professionals (Clinical Laboratories)
    • Mass Spectrometry for Clinical Laboratories
    • Molecular Diagnostics
    • Selected Pharmaceutical Company Agreements
    • Other Agreements
  • BioMosaics Inc.
  • BioReference Laboratories, Inc. (BRLI) (Part of OPKO Health, Inc.)
    • Recent Revenue History
    • Company Overview
  • bioTheranostics, Inc.
  • Biotype Diagnostic GmbH
  • Cancer Genetics, Inc.
    • Recent Revenue History
    • Company Overview
    • Pharmaceutical Company Agreements
    • Other Agreements
  • Caprion, Inc.
  • CardioDx, Inc.
  • CardioGenics Holdings Inc.
  • CareDx, Inc.
    • Recent Revenue History
    • Company Overview
  • Caris Life Sciences
  • Castle Biosciences, Inc.
  • Cepheid
    • Recent Revenue History
    • Company Overview
  • Clarient Diagnostic Services, Inc. (A NeoGenomics Company)
    • Recent Revenue History
    • Company Overview
  • CompanionDx
  • Crescendo Bioscience (A Myriad Company)
  • Cube Dx GmbH
  • Curetis AG
    • Recent Revenue History
    • Company Overview
  • Cynvenio Biosystems, Inc.
  • Dako A/S (An Agilent Company)
    • Recent Revenue History
    • Company Overview
  • Danaher Corporation
    • Recent Revenue History
    • Company Overview
  • Definiens AG (Acquired by MedImmune, Part of AstraZeneca)
  • DiaCarta, Inc.
  • DiamiR, LLC
  • Diatech Pharmacogenetics srl
  • Diaxonhit
    • Recent Revenue History
    • Company Overview
  • DNA Electronics Ltd. (DNAe)
  • EntroGen, Inc.
  • Enzo Biochem, Inc./Enzo Life Sciences, Inc./Enzo Clinical Labs, Inc.
    • Recent Revenue History
    • Company Overview
  • Epic Sciences, Inc.
  • Eutropics Pharmaceuticals
  • Exosome Diagnostics, Inc.
  • Selected Agreements
  • Foundation Medicine, Inc.
    • Recent Revenue History
    • Company Overview
  • Pharmaceutical Company Agreements
  • Agreement with Contract Research Organization
  • Agreements with Universities and Other Non-Profit Institutions
  • Agreements with Other (Non-Diagnostic) Companies
  • GeneCentric Diagnostics, Inc.
  • Genection, Inc. (An Invivoscribe Company)
  • Genelex Corporation
  • GeneNews Limited and Innovative Diagnostic Laboratory
  • Genomas, Inc.
  • GenomeDx Biosciences
  • Genomic Health, Inc.
    • Recent Revenue History
    • Company Overview
  • Genomica S.A.U.
  • Genomind
  • Genoptix (A Novartis Company)
  • GenPath Oncology
  • Grifols, S.A.
    • Recent Revenue History
    • Company Overview
  • Guardant Health, Inc.
  • HalioDx
  • Harmonyx Diagnostics
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
    • Recent Revenue History
    • Company Overview
    • Products
  • Pharmaceutical Company Agreements
  • Selected Other Agreements
  • Illumina, Inc.
    • Recent Revenue History
    • Company Overview
    • Products and Services - Overview
    • Investing in the Future
    • Companion Diagnostics
    • Agreements with Pharmaceutical Companies
    • Other Companion Diagnostic/Personalized Medicine Agreements
  • Inform Genomics, Inc.
    • Financings
    • Other Agreements
  • Inivata Ltd.
  • Insight Genetics, Inc.
    • Selected Agreements
  • InSilixa, Inc.
  • IntegraGen SA
    • Recent Revenue History
    • Company Overview
  • Invivoscribe Technologies, Inc.
  • Iris BioTechnologies Inc.
    • Recent Revenue History
    • Company Overview
  • Janssen Diagnostics/Janssen Diagnostics BVBA/Janssen Diagnostics, LLC
    • Infectious Disease
    • Oncology
  • Lab 21 (Part of the Novacyt Group of Companies)
  • Laboratory Corporation of America (LabCorp)
    • Recent Revenue History
    • Company Overview
    • Selected Examples of Companion Diagnostic/Personalized Medicine Agreements between LabCorp or Covance and Other Diagnostic Companies
  • Leica Biosystems Inc. (A Danaher Company)
    • Pharmaceutical Company Agreements in Companion Diagnostics and Personalized Medicine
    • Other Companion Diagnostic/Personalized Medicine Agreements
  • Luminex Corporation
    • Recent Revenue History
    • Company Overview
  • Mayo Medical Laboratories and Mayo Clinic
  • Medical & Biological Laboratories Co., Ltd. (MBL)/MBL International
  • Corporation
    • Recent Revenue History
    • Company Overview
  • Metabolon, Inc.
  • Metamark Genetics, Inc.
  • MIODx
  • MolecularMD Corporation
  • Monogram Biosciences (LabCorp Specialty Testing Group)
  • Multiplicom NV
  • Myriad Genetics, Inc./Myriad RBM, Inc.
    • Recent Revenue History
    • Company Overview
  • Myriad RBM
  • Pharmaceutical Company Agreements
  • NanoString Technologies, Inc.
    • Recent Revenue History
    • Company Overview
  • NantOmics (Member of the NantWorks ecosystem of companies)
  • NeoGenomics, Inc./NeoGenomics Laboratories
    • Recent Revenue History
    • Company Overview
  • NewGene Ltd.
  • New Oncology AG
  • NovellusDx
  • Nuclea Biotechnologies, Inc.
  • OncoDNA SA
  • Oncompass GmbH
  • OncoPlex Diagnostics (OncoPlexDx)(Part of NantOmics)
  • Oncospire Genomics
  • One Way Liver S.L. (OWL Metabolomics)
  • OPKO Health, Inc./OPKO Diagnostics
    • Recent Revenue History
    • Company Overview
  • BioReference Laboratories
  • OPKO Lab and 4Kscore™ Test
  • Point-of-Care Diagnostics - Claros 1 Analyzer and Sangia Microfluidic Assay Cassettes 728
  • OvaGene Oncology Inc.
  • Oxford Cancer Biomarkers Ltd
  • Oxford Gene Technology
  • Panagene Inc.
  • Personal Genome Diagnostics, Inc.
  • Protagen AG
  • QIAGEN N.V.
    • Recent Revenue History
    • Company Overview
  • QuanDx Inc.
  • Quest Diagnostics
    • Recent Revenue History
    • Company Overview
  • Qvella Corporation
  • RiboMed Biotechnologies, Inc.
  • Roche
    • Recent Revenue History
    • Company Overview
  • Roche Professional Diagnostics
  • Molecular Diagnostics
  • Tissue Diagnostics
  • Next-Generation Sequencing
  • Rosetta Genomics Ltd.
    • Recent Revenue History
    • Company Overview
    • Selected Agreements
  • Siemens Healthcare Diagnostics/Siemens Clinical Laboratory/Siemens
    • Recent Revenue History
    • Company Overview
  • Symbiodx
  • Sysmex Corporation
    • Recent Revenue History
    • Company Overview
  • Theranostics Health Inc. (Acquired by Avant Diagnostics, Inc.)
  • Thermo Fisher Scientific, Inc.
    • Recent Revenue History
    • Company Overview
  • Transgenomic, Inc.
    • Recent Revenue History
    • Company Overview
  • TrimGen Corporation
  • Trovagene, Inc.
    • Recent Revenue History
    • Company Overview
  • Ventana Medical Systems, Inc. (Member of the Roche Group)
  • WOUNDCHEK Laboratories

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Table 1-1: Worldwide Companion Diagnostic Market, 2015 and 2020

THREE: CURRENT AND EMERGING APPLICATIONS OF PERSONALIZED MEDICINE

  • Table 3-1: FDA Cleared/Approved Companion Diagnostic Tests
  • Table 3-2: Selected Major Biomarkers in Oncology Personalized Medicine Tests
  • Table 3-3: Selected Companies with Personalized Medicine Tests for Oncology
  • Table 3-4: Selected Companies with Personalized Medicine Tests for Cardiovascular Disease/Disorders
  • Table 3-5: Selected Companies with Personalized Medicine Tests for Neurological Disorders
  • Table 3-6: Selected Companies with Personalized Medicine Tests for Autoimmune and Inflammatory Disorders; Other Immune Related Conditions
  • Table 3-7: Selected Biomarkers and Other Tests for Antibiotic Resistance, and Companies Developing/Marketing these Biomarkers
  • Table 3-8: Selected Companies with Other Personalized Medicine Infectious Disease Tests
  • Table 3-9: Selected Companies with Personalized Medicine Tests for Therapeutic Drug Monitoring of Biological Drugs
  • Table 3-10: Pharmacogenomic Biomarkers in Drug Labeling
  • Table 3-11: Selected Companies with Personalized Medicine Tests for Drug Metabolism Genes
  • Table 3-12: Selected Companies with Other Personalized Medicine Tests

FOUR: BUSINESS MODELS AND DEALS - PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS

  • Table 4-1: Investments and Financings in Personalized Medicine/Companion
  • Diagnostics
  • Table 4-2: Selected Examples of Pharmaceutical Companies and Other Companies
  • That Invested in Diagnostic Companies in Personalized Medicine
  • Table 4-3: Mergers and Acquisitions in Personalized Medicine/Companion
  • Diagnostics
  • Table 4-4: Selected Examples of Pharmaceutical Companies That Acquired Diagnostic Companies or Have Diagnostic Divisions
  • Table 4-5: Collaborations between Pharmaceutical and Diagnostic Companies
  • Table 4-6: Selected Examples of Pharmaceutical That Entered into Agreements with Diagnostic Companies
  • Table 4-7: Selected Other Pharmaceutical Company Agreements
  • Table 4-8: Collaborations between Two Diagnostic Companies
  • Table 4-9: Diagnostic Company Agreements with Clinical Laboratories
  • Table 4-10: Diagnostic Company Agreements with Other Companies
  • Table 4-11: Diagnostic Company Collaborations with Universities and Other Non-Profit Research Institutes (Including Government)

SIX: PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS - MARKET ANALYSIS

  • Table 6-1: World IVD Companion Diagnostics Test Market (In Vitro Diagnostic Kits) by
  • Region (N. America, EU, ROW), 2015-2020
  • Table 6-2: World IVD Companion Diagnostics Test Market by Disease Segment, 2015(Cancer, Other)
  • Table 6-3: Wo.. 287
Back to Top